Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FONAR Co. stock logo
FONR
FONAR
$14.13
+1.2%
$12.88
$12.00
$18.68
$87.65M116,407 shs109,275 shs
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
$1.80
+2.6%
$1.35
$0.87
$7.89
$88.16M0.1309,451 shs167,552 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$1.97
-2.5%
$1.80
$1.42
$12.33
$72.25M1.4596,317 shs439,695 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$1.16
-4.1%
$1.53
$1.02
$13.40
$22.36M1.543.08 million shs53,661 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FONAR Co. stock logo
FONR
FONAR
+1.22%+9.53%+15.82%-4.38%-8.63%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
+2.56%+6.51%+35.34%+26.76%-76.38%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-2.48%-3.90%+5.35%-12.05%-82.49%
OSR Holdings, Inc. stock logo
OSRH
OSR
-4.13%-0.85%-15.33%-72.51%+115,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
FONAR Co. stock logo
FONR
FONAR
1.7698 of 5 stars
0.05.00.00.01.90.81.9
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
1.6606 of 5 stars
3.52.00.00.01.81.70.0
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
3.6446 of 5 stars
3.32.00.04.32.40.01.3
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FONAR Co. stock logo
FONR
FONAR
0.00
N/AN/AN/A
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
3.00
Buy$11.00511.11% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$9.75394.92% Upside
OSR Holdings, Inc. stock logo
OSRH
OSR
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OSRH, GUTS, FONR, and INO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$5.00 ➝ $5.00
5/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $13.00
4/15/2025
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$6.00 ➝ $5.00
3/19/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FONAR Co. stock logo
FONR
FONAR
$103.02M0.85$2.96 per share4.78$25.62 per share0.55
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
$60K1,469.31N/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$283.10K255.20N/AN/A$5.16 per share0.38
OSR Holdings, Inc. stock logo
OSRH
OSR
$4.89B0.00N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FONAR Co. stock logo
FONR
FONAR
$10.57M$1.2512.29N/A7.68%4.94%3.70%N/A
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$77.09M-$1.85N/AN/AN/A-64,849.48%N/A-57.21%N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$135.12M-$3.19N/AN/AN/AN/A-118.17%-83.47%N/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/A0.00N/AN/AN/AN/AN/A

Latest OSRH, GUTS, FONR, and INO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A-$1.04N/A-$1.04N/A$0.76 million
5/15/2025Q3 2025
FONAR Co. stock logo
FONR
FONAR
N/A$0.37N/A$0.37N/AN/A
5/13/2025Q1 2025
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$0.49-$0.49N/A-$0.49N/AN/A
5/13/2025Q1 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.74-$0.51+$0.23-$0.51$0.01 million$0.07 million
3/18/2025Q4 2024
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.87-$0.69+$0.18-$0.60$0.03 million$0.12 million
3/3/2025Q4 2024
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$0.44-$0.52-$0.08-$0.52N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
FONAR Co. stock logo
FONR
FONAR
N/AN/AN/AN/AN/A
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FONAR Co. stock logo
FONR
FONAR
N/A
11.24
9.45
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
0.60
5.58
5.57
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
3.88
3.88
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
FONAR Co. stock logo
FONR
FONAR
50.64%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
OSR Holdings, Inc. stock logo
OSRH
OSR
55.30%

Insider Ownership

CompanyInsider Ownership
FONAR Co. stock logo
FONR
FONAR
1.55%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
OSR Holdings, Inc. stock logo
OSRH
OSR
33.67%
CompanyEmployeesShares OutstandingFree FloatOptionable
FONAR Co. stock logo
FONR
FONAR
4806.20 million6.19 millionNot Optionable
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
10248.98 millionN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32036.67 million25.45 millionOptionable
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A19.28 million2.68 millionN/A

Recent News About These Companies

OSR Holdings Inc OSRH

New MarketBeat Followers Over Time

Media Sentiment Over Time

FONAR stock logo

FONAR NASDAQ:FONR

$14.03 +0.07 (+0.53%)
As of 05/23/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates in two segments, Medical Equipment, and Physician Management and Diagnostic Services. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company also offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters, and development and implementation of practice growth and marketing strategies. It owns and operates diagnostic imaging facilities in Florida; and manages MRI scanning facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1970 and is based in Melville, New York.

Fractyl Health stock logo

Fractyl Health NASDAQ:GUTS

$1.80 +0.05 (+2.56%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.71 -0.09 (-5.00%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$1.97 -0.05 (-2.48%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.97 0.00 (0.00%)
As of 05/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

OSR stock logo

OSR NASDAQ:OSRH

$1.16 -0.05 (-4.13%)
As of 05/23/2025 04:00 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.